+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID06154538

Phase II Study Comparing Immune Checkpoint Inhibitors Plus FOLFOX Chemotherapy Versus FOLFOX Alone in Neoadjuvant Treatment of Locally Advanced Colorectal Cancer

Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2025-11-28

170

Participants Needed

3

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness and safety of combining immune checkpoint inhibitors ICIs with the FOLFOX chemotherapy regimen versus using the FOLFOX regimen alone for neoadjuvant treatment in patients with locally advanced colorectal cancer. This phase II, randomized, open-label study aims to compare the pathological complete response rate, survival outcomes, and safety between these two treatment approaches. The study is sponsored by the Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Participants will be assigned to one of two groups. The first group receives ICIs via intravenous infusion on Day 1 combined with the FOLFOX regimen, which includes oxaliplatin, calcium folinate, and 5-FU administered intravenously every two weeks. The second group receives the FOLFOX regimen alone with the same dosing schedule. After three cycles of treatment, imaging will assess if the cancer is resectable, followed by surgery if appropriate. If R0 resection is achieved, preoperative treatment continues for up to nine cycles in both groups. Throughout the trial, participants will undergo assessments including imaging evaluations after three treatment cycles and surgical assessments at the time of surgery. Researchers will monitor pathological complete response rates, R0 resection rates, disease-free survival up to three years, and overall survival at one, two, and three years. Participants will be followed closely for safety and efficacy outcomes, with a maximum follow-up period of three years. The total duration of participation varies according to treatment and follow-up schedules.

CONDITIONS

Brief Title

Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer

Research Team

Q

Qian Liu

X

Xiyue Hu

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here